NCT01272466

Vaccination With Peptides From Anti-apoptotic Proteins in Relapsed Multiple Myeloma

Vaccination With Peptides Derived From Anti-apoptotic Proteins From the Bcl-2 Family, Administered in Combination With Montanide ISA-51 in Relation to Treatment With Proteasome Inhibitors in Patients With Relapsed Multiple Myeloma

• Status: Completed
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 40 (actual)
• Sponsor: Herlev Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 90 Years
• Healthy volunteers: Not accepted

Summary

Anti-apoptotic proteins from the Bcl-2 family are known to play a key role in oncogenesis and are overexpressed in myeloma cells. Studies have shown that dendritic cells exposed to proteasome inhibition present exogene antigens better than unexposed dendritic cells. Patients with relapse of multiple myeloma will be offered vaccination with peptides derived from antiapoptotic proteins from the Bcl-2 family in combination with an immunostimulatory adjuvant. The vaccination will be given in relation to treatment with the proteasome inhibitor bortezomib.

Conditions

• Relapsed Multiple Myeloma

Interventions

Type	Name	Description
BIOLOGICAL	peptides derived from antiapoptotic proteins	8 Vaccinations on day 2 and 9 in every bortezomib treatment series

Timeline

• Start date: 2010-02-01
• Primary completion: 2012-02-01
• Completion: 2015-01-01
• First posted: 2011-01-07
• Last updated: 2018-08-31

Locations

1 site across 1 country: Denmark